Efficacy and safety of omalizumab, an anti-IgE monoclonal antibody, in patients with seasonal allergic rhinitis: a systematic review.
Not Applicable
Completed
- Conditions
- seasonal allergic rhinitis
- Registration Number
- JPRN-UMIN000040561
- Lead Sponsor
- Showa University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 2270
Inclusion Criteria
Not provided
Exclusion Criteria
Case reports, case-control studies, cohort studies, and single-arm studies.
Study & Design
- Study Type
- Others,meta-analysis etc
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method daily nasal symptom score any adverse events
- Secondary Outcome Measures
Name Time Method